Exploiting ING2 Epigenetic Modulation as a Therapeutic Opportunity for Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Genetics

Background:

• Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality globally.
• Poor survival rates in metastatic NSCLC necessitate innovative therapeutic approaches.
• The Inhibitor of Growth Gene 2 (ING2) functions within the mSin3A/Histone deacetylases (HDAC) complex, regulating gene transcription.

Purpose of the Study:

• To review the role and status of ING2 and other mSin3A/HDAC members in NSCLC.
• To explore the therapeutic potential of targeting the mSin3A/HDAC complex in NSCLC.
• To propose a novel therapeutic strategy for NSCLC guided by ING2 as a biomarker.

Main Methods:

• Literature review of existing public databases focusing on ING2 and mSin3A/HDAC members in NSCLC.
• Analysis of known pharmacological properties of HDAC inhibitors.
• Development of a conceptual therapeutic model.

Main Results:

• The status of ING2 in cancer, particularly NSCLC, has been underexplored.
• The mSin3A/HDAC complex plays a significant role in NSCLC pathogenesis.
• HDAC inhibitors represent a potential therapeutic avenue.

Conclusions:

• ING2 is a potential tumor suppressor gene in NSCLC with underexplored clinical relevance.
• A therapeutic strategy leveraging ING2 as a biomarker could guide the use of HDAC inhibitors for NSCLC treatment.
• Further research into ING2's function and modulation is warranted for clinical application.